Crinetics Pharmaceuticals, Inc. (CRNX)

Crinetics Pharmaceuticals Balance Sheet

Financials in millions USD. Fiscal year is January - December.

Year	2023	2022	2021	2020	2019
Cash & Equivalents	56.2	33.97	201.2	93.59	40.83
Short-Term Investments	503.66	301.75	133.01	77.79	78.07
Cash & Cash Equivalents	559.86	335.73	334.21	171.38	118.89
Cash Growth	66.76%	0.45%	95.01%	44.15%	-27.67%
Other Current Assets	14.3	9.46	10.51	6.11	4.45
Total Current Assets	574.15	345.18	344.72	177.49	123.34
Property, Plant & Equipment	57.43	4.99	4.72	5.41	6.46
Long-Term Investments	0.47	0.67	1.08	0	0
Other Long-Term Assets	3.3	1.34	0.5	0.54	0.58
Total Long-Term Assets	61.2	6.99	6.3	5.95	7.04
Total Assets	635.35	352.18	351.02	183.45	130.38
Accounts Payable	23.2	15.35	8.47	5.59	5.5
Deferred Revenue	6.81	8.34	0	0	0
Current Debt	4.17	1.05	0	0	0
Other Current Liabilities	9.77	2.98	7.53	4.9	2.84
Total Current Liabilities	43.94	27.72	16	10.49	8.34
Long-Term Debt	47.56	2.02	3.07	4.01	4.85
Other Long-Term Liabilities	4.75	6.1	0	0.02	0.05
Total Long-Term Liabilities	52.31	8.13	3.08	4.04	4.9
Total Liabilities	96.25	35.85	19.07	14.53	13.24
Total Debt	51.73	3.08	3.07	4.01	4.85
Debt Growth	1582.21%	0.03%	-23.42%	-17.22%	-
Retained Earnings	-653.7	-439.17	-275.26	-167.61	-93.8
Comprehensive Income	0.98	-3.93	-0.38	0.03	0.15
Shareholders' Equity	539.11	316.33	331.94	168.92	117.14
Net Cash / Debt	508.13	332.65	331.13	167.37	114.04
Net Cash / Debt Growth	52.75%	0.46%	97.85%	46.76%	-30.62%
Net Cash Per Share	8.75	6.40	8.62	5.50	4.72
Working Capital	530.21	317.46	328.73	167	115
Book Value Per Share	9.28	6.08	8.64	5.55	4.84

Source: Financials are provided by Nasdaq Data Link and sourced from the audited annual (10-K) and quarterly (10-Q) reports submitted to the Securities and Exchange Commission (SEC).